Although the authors’ hypothesized that variations in the post therapy levels could be attributed to diverse sources of sPD-L1 or differences in tumor biology, it is possible that the increase observed was linked to the specific checkpoint inhibitor used. This evidence concerns the gene SPDL1 and neoplasm.